DocMorris AG Completes Rights Offering with Strong Subscription

DocMorris AG has announced the successful sale of approximately 98.7% of its subscription rights in a recent rights offering, concluding on May 21, 2025. The remaining 483,900 shares, whose rights were not exercised, will be sold in the market.

This capital increase aims to generate around CHF 200 million in gross proceeds. The funds are allocated for medium-term growth in prescription medicines and potential repayment of a CHF 95 million bond by 2026.

The new shares are listed on the SIX Swiss Exchange, with trading commencing on May 22, 2025. Payment and settlement for the rights issue are scheduled for May 26, 2025, increasing DocMorris’ share capital to CHF 510,178.83.

A banking syndicate fully underwrote the rights issue, ensuring its completion. DocMorris’ strategic focus remains on expanding its health ecosystem across Europe.